Dr. Reddy’s Laboratories (NYSE:RDY) Posts Earnings Results, Beats Expectations By $0.02 EPS

Dr. Reddy’s Laboratories (NYSE:RDY) issued its earnings results on Friday. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.02, Zacks reports. The business had revenue of $996.17 million during the quarter, compared to the consensus estimate of $83.70 billion. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%.

Dr. Reddy’s Laboratories Price Performance

RDY stock opened at $13.42 on Friday. Dr. Reddy’s Laboratories has a 52-week low of $12.26 and a 52-week high of $16.89. The business has a fifty day moving average of $13.29 and a two-hundred day moving average of $14.07. The stock has a market cap of $11.20 billion, a price-to-earnings ratio of 21.37 and a beta of 0.33. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.